Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme

NCT00014677 is registered in ClinicalTrials.gov with Neurocrine Biosciences as lead sponsor.

NCT NCT00014677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00014677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme
Lead sponsor
Neurocrine Biosciences
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2001
Completion date
July 31, 2008
Enrollment
Not reported
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors